| Item 7.01 |
Regulation FD Disclosure. |
On February 3, 2023, Intelligent Medicine
Acquisition Corp. (the “Company”) issued a press release announcing the adjournment of its special meeting until 9:30 a.m.
Eastern on February 8, 2023 (the “Press Release”). A copy of the Press Release is attached hereto and furnished as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.
The information disclosed under this Item
7.01, including the information set forth in Exhibit 99.1 hereto, is being “furnished” and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise. Such information
in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities
Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any
such filing.
Participants in the Solicitation
The Company and its directors
and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the Company’s shareholders
in respect of the Meeting and the Extension (as defined in the Proxy Statement) and related matters. Information regarding the Company’s
directors and executive officers is available in Company’s definitive proxy statement (the “Proxy Statement”) for the
Meeting filed with the U.S. Securities and Exchange Commission on January 19, 2023. Additional information regarding the participants
in the proxy solicitation and a description of their direct and indirect interests are contained in the Proxy Statement.
No Offer or Solicitation
This communication shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction
in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended.
Additional Information
The Company has filed with
the Securities and Exchange Commission (the “SEC”) the Proxy Statement in connection with the Meeting to consider and vote
upon the Extension Proposal and other matters and, beginning on or about January 20, 2023, mailed the Proxy Statement and other relevant
documents to its stockholders as of the January 9, 2023 record date for the Meeting. The Company’s stockholders and other interested
persons are advised to read the Proxy Statement and any other relevant documents that have been or will be filed with the SEC in connection
with the Company’s solicitation of proxies for the Meeting because these documents contain important information about the Company,
the Extension Proposal and related matters. Stockholders may also obtain a free copy of the Proxy Statement, as well as other relevant
documents that have been or will be filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing
a request to: Intelligent Medicine Acquisition Corp., 9001 Burdette Road, Bethesda, MD 20817, (202) 905-5834.
Forward-Looking Statements
This Current Report on Form
8-K (this “Form 8-K”) includes “forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements
of historical fact included in this Form 8-K are forward-looking statements. When used in this Form 8-K, words such
as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions, as they relate to us or our management team,
identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made
by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated
by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent
written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety
by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company,
including those set forth in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, subsequent quarterly
reports on Form 10-Q and initial public offering prospectus. The Company undertakes no obligation to update these statements
for revisions or changes after the date of this release, except as required by law.